

# Multi-Center PAMPA Study

NCT05004727

---

Status	RECRUITING
Phase	Phase 4
Sponsor	NYU Langone Health
Enrollment	176 participants

## Key Eligibility Criteria

---

### Inclusion (5)

- years old or older;
- Both male & female;
- Psoriasis diagnosis (per dermatologist) for at least 2 years (in at least 30% of participants);
- Willing and able to provide informed consent;
- Fulfillment of HR-PsO criteria (Psoriasis (PsO) patients will meet the definition of HR if they fulfill the following criteria: a) PsO duration  $>2$  years and Psoriasis Body Surface Area (BSA)  $>3\%$  and positive imaging findings in MSKPDUS defined as a RM-PsASon score of  $>3.36$

### Exclusion (7)

- Evidence of inflammatory joint pain, enthesitis and/or dactylitis on exam;
  - Current systemic immunosuppressive medication use (i.e., methotrexate, apremilast) at the time of enrollment or biologic therapy (ever);
  - RA seropositivity (mid-high RF/ACPA titers);
  - Current active malignancy;
  - History of symptomatic polyarticular OA or other joint conditions (such as RA, gout, etc) that may impair the ability to assess for PsA development
- ... and 2 more (see full listing online)

## Locations (5 total)

---

Brigham and Women's Hospital, Boston, Massachusetts, United States  
NYU Langone Health, New York, New York, United States  
University of Rochester Medical Center (URMC), Rochester, New York, United States  
... and 2 more locations